ChiCTR2400092591 版本V1.0 版本创建时间2024/11/19 16:45:41 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400092591 

最近更新日期:

Date of Last Refreshed on:

2024-11-19 16:45:36 

注册时间:

Date of Registration:

2024-11-19 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

治疗性无创呼吸支持对ABI患者拔管后再插管的影响:一项多中心随机对照研究

Public title:

Effect of therapeutic noninvasive respiratory support on reintubation after extubation in patients with ABI: a multicenter randomized controlled study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

治疗性无创呼吸支持对ABI患者拔管后再插管的影响:一项多中心随机对照研究

Scientific title:

Effect of therapeutic noninvasive respiratory support on reintubation after extubation in patients with ABI: a multicenter randomized controlled study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

汪建文 

研究负责人:

汪建文 

Applicant:

Wang Jianwen 

Study leader:

Wang Jianwen 

申请注册联系人电话:

Applicant telephone:

+86 137 0806 8948

研究负责人电话:

Study leader's telephone:

+86 137 0806 8948

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

799909495@qq.com

研究负责人电子邮件:

Study leader's E-mail:

799909495@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国四川省成都市武侯区国学巷37号

研究负责人通讯地址:

中国四川省成都市武侯区国学巷37号

Applicant address:

37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province, China

Study leader's address:

37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

四川大学华西医院

Applicant's institution:

West China Hospital, Sichuan University

研究负责人所在单位:

四川大学华西医院

Affiliation of the Leader:

West China Hospital, Sichuan University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024年审(1892)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川大学华西医院生物医学伦理审查委员会

Name of the ethic committee:

Biomedical Ethics Review Committee, West China Hospital, Sichuan University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-11-05 00:00:00

伦理委员会联系人:

邓绍林

Contact Name of the ethic committee:

Deng Shaolin

伦理委员会联系地址:

中国四川省成都市武侯区国学巷37号八角亭2105

Contact Address of the ethic committee:

2105 Bajiaoting, 37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 189 8060 1004

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

四川大学华西医院

Primary sponsor:

West China Hospital, Sichuan University

研究实施负责(组长)单位地址:

中国四川省成都市武侯区国学巷37号

Primary sponsor's address:

37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川省

市(区县):

成都市

Country:

China

Province:

Sichuan Province

City:

Chengdu City

单位(医院):

四川大学华西医院

具体地址:

中国四川省成都市武侯区国学巷37号

Institution
hospital:

West China Hospital, Sichuan University

Address:

37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province, China

经费或物资来源:

四川省自然科学基金项目

Source(s) of funding:

The Natural Science Foundation of Sichuan Province

Target disease:

Acute Brain Injury

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

旨在确定治疗性无创正压通气和治疗性高流量氧疗对ABI患者拔管后再插管的影响。我们计划进行一项多中心随机对照研究,研究对象是在ICU中脱离机械通气的脑损伤患者。  

Objectives of Study:

To determine the effects of therapeutic noninvasive positive pressure ventilation and therapeutic high-flow oxygen therapy on reintubation after extubation in patients with ABI. We planned to conduct a multicenter randomized controlled study of brain injury patients weaned from mechanical ventilation in the ICU.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①年龄≥18岁;②入科时急性脑损伤ABI[符合创伤性脑损伤(TBI)、蛛网膜下腔动脉瘤性出血(SAH)、颅内出血(ICH)、急性缺血性中风(AIS)、中枢神经系统感染(脑脓肿、脓肿、脑膜炎、脑炎、脑肿瘤)或颅脑术后(肿瘤切除术、脑血管瘤手术等)诊断]的气管插管有创通气患者。

Inclusion criteria

① Age ≥18 years old; ② Acute brain injury ABI[in line with traumatic brain injury (TBI), subarachnoid aneurysmal hemorrhage (SAH), intracranial hemorrhage (ICH), acute ischemic stroke (AIS), central nervous system infection (brain abscess, abscess, meningitis, encephalitis, brain tumor) or craniocerebral surgery (tumor resection, cerebral hemangioma surgery, etc.) diagnosis] at admission Patients were intubated with invasive ventilation.

排除标准:

年龄<18岁、妊娠、心脏骤停后复苏、拔管前死亡、生命终止拔管、ICU入院后24小时内停止生命维持治疗(WLST)、在ICU入院前有气管切开术者。

Exclusion criteria:

Age < 18 years, pregnancy, resuscitation after cardiac arrest, death before extubation, end of life extubation, withdrawal of life support within 24 hours after ICU admission (WLST), and tracheotomy before ICU admission.

研究实施时间:

Study execute time:

From 2024-11-25 00:00:00 To 2025-11-05 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-11-25 00:00:00 To 2025-11-05 00:00:00  

干预措施:

Interventions:

组别:

无创正压通气组

样本量:

114

Group:

Noninvasive positive pressure ventilation group

Sample size:

干预措施:

无创正压通气

干预措施代码:

Intervention:

Noninvasive positive pressure ventilation

Intervention code:

组别:

高流量氧疗组

样本量:

114

Group:

high flow oxygen therapy group

Sample size:

干预措施:

高流量氧疗

干预措施代码:

Intervention:

high flow oxygen therapy

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川省 

市(区县):

成都市 

Country:

China 

Province:

Sichuan Province 

City:

Chengdu City 

单位(医院):

四川大学华西医院 

单位级别:

三甲 

Institution
hospital:

West China Hospital, Sichuan University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川省 

市(区县):

成都市 

Country:

China 

Province:

Sichuan Province 

City:

Chengdu City 

单位(医院):

四川大学华西医院上锦分院/成都上锦南府医院 

单位级别:

三甲 

Institution
hospital:

Shangjin Branch of West China Hospital, Sichuan University/Shangjin Nanfu Hospital, Chengdu

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

拔管后再插管率

指标类型:

主要指标

Outcome:

Rate of reintubation after extubation

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

ICU和医院死亡率

指标类型:

次要指标

Outcome:

ICU and hospital mortality

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究负责人根据计算机随机数字分组

Randomization Procedure (please state who generates the random number sequence and by what method):

Study leaders assigned groups according to computerized random numbers

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

开放

Blinding:

Open label

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NO

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据将来自患者的床边护理图表、医疗记录、病理结果、电子监测器和采访亲属。这些数据将被输入纸质数据收集表格,称为护理记录表格(CRF),随后输入电子数据库。数据收集将定期进行,直到最终出院。在计划出院后,未对患者及其家属进行随访。收集的数据将包括上面描述的主要和次要结果。我们还将收集其他数据,包括:1.纳入研究:人口统计学变量(年龄、性别、入院后24小时内的APACHE II评分)和初步诊断。2.在机械通气的第一天以及从第一次成功的自主呼吸试验到拔管期间记录生理参数,包括生命体征、格拉斯哥昏迷量表评分、ACS评分、STAGE评分[6]、呼吸机模式和参数、24小时液体出入量、实验室检查结果、血气分析以及镇静剂和镇痛剂的使用。此外,记录的临床结果参数如下:拔管失败数、气管造口术率、机械通气持续时间、在ICU和医院停留时间、院内肺炎、死亡率和费用。3.拔管时:动脉血气,APACHE II评分,和类固醇的使用。4.拔管后:与拔管相关的并发症、不良事件、再拔管的原因和拔管后呼吸衰竭的原因。5.无创呼吸支持相关内容:NIV时间和高流量时间,应用无创呼吸支持后每日参数包括包括生命体征、格拉斯哥昏迷量表评分、ACS评分、STAGE评分、呼吸机模式和参数、24小时液体出入量、血气分析,随访患者至28天。6.记录在ICU、住院时间及出院状态。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data will come from patient bedside care charts, medical records, pathology findings, electronic monitors, and interviews with relatives. These data will be entered into a paper data collection form, called a Nursing Record Form (CRF), and subsequently into an electronic database. Data collection will be performed regularly until final discharge. Patients and their families were not followed up after the planned discharge. The data collected will include the primary and secondary outcomes described above. We will also collect additional data including: 1. Included in the study: Demographic variables (age, sex, APACHE II score within 24 hours after admission) and initial diagnosis. Physiological parameters were recorded on the first day of mechanical ventilation and from the first successful spontaneous breathing trial to extubation, including vital signs, Glasgow Coma Scale score, ACS score, STAGE score [6], ventilator mode and parameters, 24-hour fluid intake and output, laboratory test results, blood gas analysis, and use of sedatives and analgesics. In addition, the following clinical outcome parameters were recorded: number of extubation failures, tracheostomy rate, duration of mechanical ventilation, length of stay in ICU and hospital, in-hospital pneumonia, mortality, and costs. 3. Time of extubation: arterial blood gases, APACHE II score, and steroid use. 4. After extubation: complications related to extubation, adverse events, reasons for re-extubation, and reasons for respiratory failure after extubation. 5. Noninvasive respiratory support: NIV time and high flow time, daily parameters after noninvasive respiratory support including vital signs, Glasgow coma scale score, ACS score, STAGE score, ventilator mode and parameters, 24-hour fluid intake and output, blood gas analysis, patients were followed up to 28 days. 6. ICU stay, length of hospital stay, and discharge status were recorded.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-11-19 16:45:36